Cerus (NASDAQ:CERS) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Thursday.

Other research analysts also recently issued reports about the stock. ValuEngine upgraded shares of Cerus from a “sell” rating to a “hold” rating in a research report on Wednesday. Zacks Investment Research upgraded shares of Cerus from a “sell” rating to a “hold” rating in a research report on Wednesday. BTIG Research restated a “hold” rating on shares of Cerus in a research report on Saturday, March 10th. Cantor Fitzgerald restated an “overweight” rating and set a $5.00 target price on shares of Cerus in a research report on Friday, January 5th. Finally, Robert W. Baird restated a “buy” rating and set a $5.00 target price on shares of Cerus in a research report on Friday, December 1st. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $5.00.

How to Become a New Pot Stock Millionaire

Cerus (NASDAQ CERS) opened at $5.42 on Thursday. The stock has a market cap of $674.33, a price-to-earnings ratio of -9.68 and a beta of 2.16. Cerus has a 1 year low of $1.93 and a 1 year high of $5.43. The company has a current ratio of 3.89, a quick ratio of 3.26 and a debt-to-equity ratio of 0.77.

Cerus (NASDAQ:CERS) last posted its earnings results on Thursday, March 8th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The company had revenue of $16.20 million during the quarter, compared to the consensus estimate of $17.53 million. Cerus had a negative net margin of 139.06% and a negative return on equity of 154.46%. The firm’s quarterly revenue was up 60.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.13) earnings per share. equities analysts anticipate that Cerus will post -0.43 EPS for the current fiscal year.

In other Cerus news, CEO William Mariner Greenman sold 7,735 shares of Cerus stock in a transaction on Monday, March 12th. The shares were sold at an average price of $4.80, for a total value of $37,128.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 14,381 shares of company stock valued at $69,685 in the last ninety days. 7.40% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Premier Asset Management LLC purchased a new position in Cerus in the third quarter valued at $348,000. Vanguard Group Inc. increased its holdings in Cerus by 3.9% in the second quarter. Vanguard Group Inc. now owns 4,892,503 shares of the biotechnology company’s stock valued at $12,281,000 after buying an additional 184,076 shares in the last quarter. Elk Creek Partners LLC increased its holdings in Cerus by 6.8% in the third quarter. Elk Creek Partners LLC now owns 6,128,026 shares of the biotechnology company’s stock valued at $16,730,000 after buying an additional 388,741 shares in the last quarter. Northern Trust Corp increased its holdings in Cerus by 3.2% in the second quarter. Northern Trust Corp now owns 1,269,773 shares of the biotechnology company’s stock valued at $3,186,000 after buying an additional 39,684 shares in the last quarter. Finally, ARK Investment Management LLC increased its holdings in Cerus by 32.8% in the fourth quarter. ARK Investment Management LLC now owns 3,564,373 shares of the biotechnology company’s stock valued at $12,048,000 after buying an additional 881,171 shares in the last quarter. 56.27% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.dailypolitical.com/2018/03/15/cerus-cers-upgraded-to-strong-buy-at-bidaskclub.html.

About Cerus

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.